<p>在全球市場波動的一週中，由於關税不確定性和經濟信號混雜，美國股市收盤下跌，標準普爾 500 指數小幅下滑 0.24%。儘管面臨這些挑戰，小型股通常在市場情緒波動時提供獨特的增長機會。在這種環境下，識別小型股領域中未被發現的潛力股需要關注那些在經濟環境變化中展現出韌性和潛力的公司。</p>
<h3>基本面強勁的十大未被發現的潛力股</h3>
<table>
<thead>
<tr>
<th>名稱</th>
<th>負債權益比</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>健康評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>Darya-Varia Laboratoria</td>
<td>NA</td>
<td>1.44%</td>
<td>-11.65%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Quemchi</td>
<td>0.66%</td>
<td>82.67%</td>
<td>21.69%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Wilson Bank Holding</td>
<td>NA</td>
<td>7.87%</td>
<td>8.22%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Ovostar Union</td>
<td>0.01%</td>
<td>10.19%</td>
<td>49.85%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Aesler Grup Internasional</td>
<td>NA</td>
<td>-17.61%</td>
<td>-40.21%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>National General Insurance (P.J.S.C.)</td>
<td>NA</td>
<td>11.69%</td>
<td>30.36%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Watt's</td>
<td>70.56%</td>
<td>7.69%</td>
<td>-0.53%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Hollyland (China) Electronics Technology</td>
<td>3.46%</td>
<td>13.95%</td>
<td>11.27%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Al-Deera Holding Company K.P.S.C</td>
<td>6.11%</td>
<td>51.44%</td>
<td>59.77%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Central Cooperative Bank AD</td>
<td>4.88%</td>
<td>37.94%</td>
<td>537.05%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們篩選出的 4699 只股票的完整列表，均為基本面強勁的未被發現的潛力股。</p>
<p>讓我們回顧一些篩選股票中的顯著選擇。</p>
<h2>OrbusNeich 醫療集團控股（SEHK:6929）</h2>
<p><strong>Simply Wall St 價值評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> OrbusNeich 醫療集團控股有限公司是一家投資控股公司，專注於心髒病和外周血管疾病的醫療設備的研究、開發、製造和營銷，市場覆蓋日本、歐洲和美國，市值為 29 億港元。</p>
<p><strong>運營：</strong> 該公司從其外科和醫療設備部門產生的收入為 1.5137 億美元。</p>
<p>OrbusNeich 醫療集團控股在醫療設備領域是一家顯著的參與者，過去一年盈利增長 8.6%，超過行業的-4.3%。該公司目前的交易價格比其估計的公允價值低 78.2%，並且現金超過總債務，顯示出良好的財務基礎。最近的進展包括召開特別股東大會，旨在修訂股份發行和回購的授權，可能會影響未來的資本結構。預計盈利年增長率為 13.83%，為尋求被低估的醫療創新機會的投資者提供了引人注目的前景。</p>
<ul>
<li>點擊這裏瞭解 OrbusNeich 醫療集團控股的細節分析健康報告。</li>
<li>瞭解 OrbusNeich 醫療集團控股的歷史表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/95005aef-37fc-410f-afe4-96444d1d719e/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/95005aef-37fc-410f-afe4-96444d1d719e/chart/earnings-and-revenue-growth"/></p>
<p>SEHK:6929 截至 2025 年 2 月的盈利和收入增長</p>
<h2>智洋創新科技（SHSE:688191）</h2>
<p><strong>Simply Wall St 價值評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 智洋創新科技有限公司是一家總部位於中國的人工智能公司，市值為 30.8 億人民幣。</p>
<p><strong>運營：</strong> 智洋創新科技主要通過其人工智能解決方案產生收入。公司的財務表現以 45% 的毛利率為亮點，表明在管理生產成本相對於銷售方面的效率。</p>
<p>智洋創新科技在科技領域是一家較小的參與者，過去一年盈利增長 27.7%，超過了更廣泛的電氣行業的 1.1%。儘管過去五年經歷了年盈利下降 26.3% 的挑戰，但最近的表現突顯了其韌性和復甦潛力。該公司能夠舒適地覆蓋其利息義務，並且相對於其總債務保持健康的現金狀況，債務權益比在五年內從零上升至 11.3%。憑藉正的自由現金流和高質量的盈利，智洋似乎在其行業內有進一步探索的潛力。</p>
<ul>
<li>點擊這裏訪問我們的完整健康分析報告，以瞭解智洋創新科技的動態。</li>
<li>查看我們的歷史表現報告，以獲取智洋創新科技過去表現的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6aebebee-9140-4380-8187-1b22dfe740b9/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6aebebee-9140-4380-8187-1b22dfe740b9/chart/debt-equity-history-analysis"/></p>
<p>SHSE:688191 截至 2025 年 2 月的負債權益比</p>
<h2>Kamei（TSE:8037）</h2>
<p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Kamei Corporation 是一家在日本及國際上運作的一般貿易公司，市值為 600.2 億日元。</p>
<p><strong>運營：</strong> Kamei Corporation 的主要收入來源包括 2791 億日元的能源業務和 867.8 億日元的海外/貿易業務，其次是 752.9 億日元的汽車相關業務。公司的淨利潤率反映了其在這些多元化領域有效管理成本的能力。</p>
<p>Kamei 在貿易分銷商領域是一家較小的參與者，過去一年盈利增長 14.9%，超過了行業的 3.4%。該公司目前的交易價格比其估計的公允價值低 93.1%，暗示潛在的低估。在過去五年中，Kamei 的負債權益比從 51% 改善至 28.9%，顯示出更好的財務健康和降低的槓桿風險。最近，Kamei 宣佈了一項 40 億日元的股份回購計劃，以提升股東價值並適應市場變化；這一舉措反映了對未來前景的信心和資本管理的戰略靈活性。</p>
<ul>
<li>通過我們的綜合健康報告深入瞭解 Kamei 的複雜性。</li>
<li>通過訪問我們的歷史表現報告評估 Kamei 的歷史表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/dc868fea-bc7d-4c3b-ad20-a91f73bb57cd/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/dc868fea-bc7d-4c3b-ad20-a91f73bb57cd/chart/debt-equity-history-analysis"/></p>
<p>TSE:8037 截至 2025 年 2 月的債務與股本比率</p>
<h2>總結</h2>
<ul>
<li>點擊這裏解鎖我們包含 4699 個具有強大基本面的未被發現的投資機會的綜合列表。</li>
<li>已經擁有這些公司？通過將您的投資組合與 Simply Wall St 連接，清晰化您的投資決策，您可以輕鬆監控所有股票的關鍵指標。</li>
<li>使用 Simply Wall St 應用程序提升您的投資能力，享受跨越每個大洲的市場情報的免費訪問。</li>
</ul>
<h2>尋找其他投資？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>

業聚醫療

智洋創新

8037

<p>在全球市場波動的一週中，美國股市小幅下跌，標準普爾 500 指數下跌了 0.24%。儘管如此，小型股仍然呈現出增長機會。值得注意的小型公司包括業聚醫療、智洋創新和亀井株式會社，這些公司都展現出強勁的基本面和增長潛力。業聚醫療專注於醫療設備，智洋創新專注於人工智能解決方案，而亀井株式會社則作為一家綜合貿易公司運營。每家公司都展現出韌性和良好的財務健康，使其成為尋求被低估機會的投資者的有吸引力的選擇</p>

<p>In a week marked by global market fluctuations, U.S. stocks ended lower amid tariff uncertainties and mixed economic signals, with the S&amp;P 500 Index experiencing a slight decline of 0.24%. Despite these challenges, small-cap stocks often present unique opportunities for growth, particularly when broader market sentiment is volatile. In this environment, identifying undiscovered gems within the small-cap sector requires an eye for companies that demonstrate resilience and potential amidst shifting economic landscapes.</p>
<div class="lb-trans"><p>在全球市場波動的一週中，由於關税不確定性和經濟信號混雜，美國股市收盤下跌，標準普爾 500 指數小幅下滑 0.24%。儘管面臨這些挑戰，小型股通常在市場情緒波動時提供獨特的增長機會。在這種環境下，識別小型股領域中未被發現的潛力股需要關注那些在經濟環境變化中展現出韌性和潛力的公司。</p>
</div><h3>Top 10 Undiscovered Gems With Strong Fundamentals</h3>
<div class="lb-trans"><h3>基本面強勁的十大未被發現的潛力股</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Debt To Equity</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Health Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Darya-Varia Laboratoria</td>
<td>NA</td>
<td>1.44%</td>
<td>-11.65%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Quemchi</td>
<td>0.66%</td>
<td>82.67%</td>
<td>21.69%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Wilson Bank Holding</td>
<td>NA</td>
<td>7.87%</td>
<td>8.22%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Ovostar Union</td>
<td>0.01%</td>
<td>10.19%</td>
<td>49.85%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Aesler Grup Internasional</td>
<td>NA</td>
<td>-17.61%</td>
<td>-40.21%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>National General Insurance (P.J.S.C.)</td>
<td>NA</td>
<td>11.69%</td>
<td>30.36%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Watt's</td>
<td>70.56%</td>
<td>7.69%</td>
<td>-0.53%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Hollyland (China) Electronics Technology</td>
<td>3.46%</td>
<td>13.95%</td>
<td>11.27%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Al-Deera Holding Company K.P.S.C</td>
<td>6.11%</td>
<td>51.44%</td>
<td>59.77%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Central Cooperative Bank AD</td>
<td>4.88%</td>
<td>37.94%</td>
<td>537.05%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名稱</th>
<th>負債權益比</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>健康評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>Darya-Varia Laboratoria</td>
<td>NA</td>
<td>1.44%</td>
<td>-11.65%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Quemchi</td>
<td>0.66%</td>
<td>82.67%</td>
<td>21.69%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Wilson Bank Holding</td>
<td>NA</td>
<td>7.87%</td>
<td>8.22%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Ovostar Union</td>
<td>0.01%</td>
<td>10.19%</td>
<td>49.85%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Aesler Grup Internasional</td>
<td>NA</td>
<td>-17.61%</td>
<td>-40.21%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>National General Insurance (P.J.S.C.)</td>
<td>NA</td>
<td>11.69%</td>
<td>30.36%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Watt's</td>
<td>70.56%</td>
<td>7.69%</td>
<td>-0.53%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Hollyland (China) Electronics Technology</td>
<td>3.46%</td>
<td>13.95%</td>
<td>11.27%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Al-Deera Holding Company K.P.S.C</td>
<td>6.11%</td>
<td>51.44%</td>
<td>59.77%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Central Cooperative Bank AD</td>
<td>4.88%</td>
<td>37.94%</td>
<td>537.05%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 4699 stocks from our Undiscovered Gems With Strong Fundamentals screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們篩選出的 4699 只股票的完整列表，均為基本面強勁的未被發現的潛力股。</p>
</div><p>Let's review some notable picks from our screened stocks.</p>
<div class="lb-trans"><p>讓我們回顧一些篩選股票中的顯著選擇。</p>
</div><h2>OrbusNeich Medical Group Holdings (SEHK:6929)</h2>
<div class="lb-trans"><h2>OrbusNeich 醫療集團控股（SEHK:6929）</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 價值評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> OrbusNeich Medical Group Holdings Limited is an investment holding company that focuses on the research, development, manufacturing, and marketing of medical devices for coronary and peripheral vascular diseases across various global markets including Japan, Europe, and the United States with a market cap of HK$2.90 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> OrbusNeich 醫療集團控股有限公司是一家投資控股公司，專注於心髒病和外周血管疾病的醫療設備的研究、開發、製造和營銷，市場覆蓋日本、歐洲和美國，市值為 29 億港元。</p>
</div><p><strong>Operations:</strong> The company generates revenue of $151.37 million from its surgical and medical equipment segment.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司從其外科和醫療設備部門產生的收入為 1.5137 億美元。</p>
</div><p>OrbusNeich Medical Group Holdings, a notable player in the medical equipment sector, has demonstrated robust financial health with earnings growing by 8.6% over the past year, outpacing the industry's -4.3%. The company is trading at a significant discount of 78.2% below its estimated fair value and maintains more cash than total debt, indicating solid financial footing. Recent developments include a special shareholders meeting aimed at revising mandates for share issuance and repurchase, potentially impacting future capital structure. With earnings forecasted to grow annually by 13.83%, it presents intriguing prospects for investors seeking undervalued opportunities in healthcare innovation.</p>
<div class="lb-trans"><p>OrbusNeich 醫療集團控股在醫療設備領域是一家顯著的參與者，過去一年盈利增長 8.6%，超過行業的-4.3%。該公司目前的交易價格比其估計的公允價值低 78.2%，並且現金超過總債務，顯示出良好的財務基礎。最近的進展包括召開特別股東大會，旨在修訂股份發行和回購的授權，可能會影響未來的資本結構。預計盈利年增長率為 13.83%，為尋求被低估的醫療創新機會的投資者提供了引人注目的前景。</p>
</div><ul>
<li>Click here to discover the nuances of OrbusNeich Medical Group Holdings with our detailed analytical health report.</li>
<li>Learn about OrbusNeich Medical Group Holdings' historical performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏瞭解 OrbusNeich 醫療集團控股的細節分析健康報告。</li>
<li>瞭解 OrbusNeich 醫療集團控股的歷史表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/95005aef-37fc-410f-afe4-96444d1d719e/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/95005aef-37fc-410f-afe4-96444d1d719e/chart/earnings-and-revenue-growth"/></p>
<p>SEHK:6929 Earnings and Revenue Growth as at Feb 2025</p>
<div class="lb-trans"><p>SEHK:6929 截至 2025 年 2 月的盈利和收入增長</p>
</div><h2>Zhiyang Innovation Technology (SHSE:688191)</h2>
<div class="lb-trans"><h2>智洋創新科技（SHSE:688191）</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 價值評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Zhiyang Innovation Technology Co., Ltd. is an artificial intelligence company based in China with a market capitalization of CN¥3.08 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 智洋創新科技有限公司是一家總部位於中國的人工智能公司，市值為 30.8 億人民幣。</p>
</div><p><strong>Operations:</strong> Zhiyang Innovation Technology generates revenue primarily through its artificial intelligence solutions. The company's financial performance is highlighted by a gross profit margin of 45%, indicating efficiency in managing production costs relative to sales.</p>
<div class="lb-trans"><p><strong>運營：</strong> 智洋創新科技主要通過其人工智能解決方案產生收入。公司的財務表現以 45% 的毛利率為亮點，表明在管理生產成本相對於銷售方面的效率。</p>
</div><p>Zhiyang Innovation Technology, a smaller player in the tech landscape, has shown significant earnings growth of 27.7% over the past year, outpacing the broader Electrical industry at 1.1%. Despite a challenging five-year period with annual earnings dropping by 26.3%, recent performance highlights resilience and potential for recovery. The company is comfortably covering its interest obligations and maintains a healthy cash position relative to its total debt, which has risen to an 11.3% debt-to-equity ratio from zero over five years. With positive free cash flow and high-quality earnings, Zhiyang seems poised for further exploration within its sector.</p>
<div class="lb-trans"><p>智洋創新科技在科技領域是一家較小的參與者，過去一年盈利增長 27.7%，超過了更廣泛的電氣行業的 1.1%。儘管過去五年經歷了年盈利下降 26.3% 的挑戰，但最近的表現突顯了其韌性和復甦潛力。該公司能夠舒適地覆蓋其利息義務，並且相對於其總債務保持健康的現金狀況，債務權益比在五年內從零上升至 11.3%。憑藉正的自由現金流和高質量的盈利，智洋似乎在其行業內有進一步探索的潛力。</p>
</div><ul>
<li>Click here and access our complete health analysis report to understand the dynamics of Zhiyang Innovation Technology.</li>
<li>Review our historical performance report to gain insights into Zhiyang Innovation Technology's's past performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們的完整健康分析報告，以瞭解智洋創新科技的動態。</li>
<li>查看我們的歷史表現報告，以獲取智洋創新科技過去表現的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6aebebee-9140-4380-8187-1b22dfe740b9/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/6aebebee-9140-4380-8187-1b22dfe740b9/chart/debt-equity-history-analysis"/></p>
<p>SHSE:688191 Debt to Equity as at Feb 2025</p>
<div class="lb-trans"><p>SHSE:688191 截至 2025 年 2 月的負債權益比</p>
</div><h2>Kamei (TSE:8037)</h2>
<div class="lb-trans"><h2>Kamei（TSE:8037）</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Kamei Corporation functions as a general trading company both in Japan and internationally, with a market capitalization of ¥60.02 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Kamei Corporation 是一家在日本及國際上運作的一般貿易公司，市值為 600.2 億日元。</p>
</div><p><strong>Operations:</strong> The primary revenue streams for Kamei Corporation include the Energy Business at ¥279.10 billion and the Overseas/Trade Business at ¥86.78 billion, followed by the Automotive Related Business contributing ¥75.29 billion. The company’s net profit margin reflects its ability to manage costs effectively across these diverse segments.</p>
<div class="lb-trans"><p><strong>運營：</strong> Kamei Corporation 的主要收入來源包括 2791 億日元的能源業務和 867.8 億日元的海外/貿易業務，其次是 752.9 億日元的汽車相關業務。公司的淨利潤率反映了其在這些多元化領域有效管理成本的能力。</p>
</div><p>Kamei, a smaller player in the trade distributors sector, has shown impressive earnings growth of 14.9% over the past year, outpacing the industry's 3.4%. The company is trading at a significant discount of 93.1% below its estimated fair value, suggesting potential undervaluation. Over five years, Kamei's debt to equity ratio improved from 51% to 28.9%, indicating better financial health and reduced leverage risks. Recently, Kamei announced a share repurchase program for ¥4 billion to enhance shareholder value and adapt to market changes; this move reflects confidence in its future prospects and strategic flexibility in capital management.</p>
<div class="lb-trans"><p>Kamei 在貿易分銷商領域是一家較小的參與者，過去一年盈利增長 14.9%，超過了行業的 3.4%。該公司目前的交易價格比其估計的公允價值低 93.1%，暗示潛在的低估。在過去五年中，Kamei 的負債權益比從 51% 改善至 28.9%，顯示出更好的財務健康和降低的槓桿風險。最近，Kamei 宣佈了一項 40 億日元的股份回購計劃，以提升股東價值並適應市場變化；這一舉措反映了對未來前景的信心和資本管理的戰略靈活性。</p>
</div><ul>
<li>Navigate through the intricacies of Kamei with our comprehensive health report here.</li>
<li>Evaluate Kamei's historical performance by accessing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過我們的綜合健康報告深入瞭解 Kamei 的複雜性。</li>
<li>通過訪問我們的歷史表現報告評估 Kamei 的歷史表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/dc868fea-bc7d-4c3b-ad20-a91f73bb57cd/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/dc868fea-bc7d-4c3b-ad20-a91f73bb57cd/chart/debt-equity-history-analysis"/></p>
<p>TSE:8037 Debt to Equity as at Feb 2025</p>
<div class="lb-trans"><p>TSE:8037 截至 2025 年 2 月的債務與股本比率</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>總結</h2>
</div><ul>
<li>Unlock our comprehensive list of 4699 Undiscovered Gems With Strong Fundamentals by clicking here.</li>
<li>Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.</li>
<li>Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏解鎖我們包含 4699 個具有強大基本面的未被發現的投資機會的綜合列表。</li>
<li>已經擁有這些公司？通過將您的投資組合與 Simply Wall St 連接，清晰化您的投資決策，您可以輕鬆監控所有股票的關鍵指標。</li>
<li>使用 Simply Wall St 應用程序提升您的投資能力，享受跨越每個大洲的市場情報的免費訪問。</li>
</ul>
</div><h2>Seeking Other Investments?</h2>
<div class="lb-trans"><h2>尋找其他投資？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>
</div>

未被發現的寶石以及另外兩個具有潛力的小盤股